GlassScriptPhysician profile
Kess Mughelli-Ogden
NPI 1215223284
$3,045.68
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $743 · 2021: $234 · 2022: $584 · 2023: $1,021 · 2024: $32.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $580.38 | 2019-2023 | Spravato, Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $392.80 | 2019-2023 | Abilify Maintena, Rexulti |
| Abbvie INC. | $390.38 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $365.77 | 2019-2023 | Uzedy, Austedo, Austedo Xr |
| Indivior INC. | $326.29 | 2022-2023 | Perseris |
| Allergan, INC. | $285.62 | 2019-2020 | |
| Lundbeck LLC | $209.36 | 2020-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $192.73 | 2019-2023 | Ingrezza |
| Alkermes, INC. | $174.40 | 2019-2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $75.93 | 2019-2020 | |
| Eisai INC. | $20.19 | 2020 | |
| Ironshore Pharmaceuticals INC. | $18.63 | 2019 | |
| Bausch Health US, LLC | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kess Mughelli-Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.